36种药品纳入医保药品目录 平均价格降幅达44%

The prices of 36 expensive drugs - half of them for cancer treatment - are now covered by medical insurance, after the authorities negotiated substantial price reductions.

在有关部门通过谈判实现大幅降价后，36种高价药现已纳入医保报销范围，其中半数是癌症治疗药物。

The Ministry of Human Resources and Social Security negotiated with pharmaceutical manufacturers on 44 drugs and managed to cut prices of 36 of them to be acceptable for coverage by the medical insurance fund, Xu Yanjun, a fund management official at the ministry, said at a news conference.

日前，人力资源和社会保障部的基金管理官员徐延君在新闻发布会上表示，人社部与制药企业就44种药品进行了谈判，成功将其中36种药品的价格降至医保基金报销可接受的水平。

Compared with retail prices last year, prices of these drugs have decreased by 44% on average, he said.

徐延君称，与去年的零售价相比，这些药物的价格平均下降了44%。

Five of the drugs are traditional Chinese medicines and 22 are imported Western medicines.

在这些药品中，其中5种是中药，22种是进口的西方药物。

Prices of the drugs may be adjusted further when the contracts between the government and the manufacturers expire at the end of 2019, said Yan Qinghui, the ministry's deputy director of medical insurance.

人社部医保司副司长颜清辉表示，政府与药企签订的协议将于2019年底到期，届时这些药品的价格可能会作进一步调整。

"We hoped we could make full use of the advantages of the fund's group purchasing to include more drugs in the medical insurance directory," Yan said.

颜清辉说道：“我们希望我们能充分利用基金组织购买的优势，在医疗保险目录中加入更多的药物。”